Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

The novel nonapeptide acein targets angiotensin converting enzyme in the brain and induces dopamine release.

Neasta J, Valmalle C, Coyne AC, Carnazzi E, Subra G, Galleyrand JC, Gagne D, M'Kadmi C, Bernad N, Bergé G, Cantel S, Marin P, Marie J, Banères JL, Kemel ML, Daugé V, Puget K, Martinez J.

Br J Pharmacol. 2016 Apr;173(8):1314-28. doi: 10.1111/bph.13424. Epub 2016 Mar 8.

2.

Homogeneous time-resolved fluorescence-based assay to screen for ligands targeting the growth hormone secretagogue receptor type 1a.

Leyris JP, Roux T, Trinquet E, Verdié P, Fehrentz JA, Oueslati N, Douzon S, Bourrier E, Lamarque L, Gagne D, Galleyrand JC, M'kadmi C, Martinez J, Mary S, Banères JL, Marie J.

Anal Biochem. 2011 Jan 15;408(2):253-62. doi: 10.1016/j.ab.2010.09.030. Epub 2010 Sep 24.

PMID:
20937574
3.

Involvement of tryptophan W276 and of two surrounding amino acid residues in the high constitutive activity of the ghrelin receptor GHS-R1a.

Gozé C, Bergé G, M'Kadmi C, Floquet N, Gagne D, Galleyrand JC, Fehrentz JA, Martinez J.

Eur J Pharmacol. 2010 Sep 25;643(2-3):153-61. doi: 10.1016/j.ejphar.2010.06.018. Epub 2010 Jun 30.

PMID:
20599926
4.

Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme.

Dalkas GA, Marchand D, Galleyrand JC, Martinez J, Spyroulias GA, Cordopatis P, Cavelier F.

J Pept Sci. 2010 Feb;16(2):91-7. doi: 10.1002/psc.1201.

PMID:
20014331
5.

Activation of the ghrelin receptor is described by a privileged collective motion: a model for constitutive and agonist-induced activation of a sub-class A G-protein coupled receptor (GPCR).

Floquet N, M'Kadmi C, Perahia D, Gagne D, Bergé G, Marie J, Banères JL, Galleyrand JC, Fehrentz JA, Martinez J.

J Mol Biol. 2010 Jan 29;395(4):769-84. doi: 10.1016/j.jmb.2009.09.051. Epub 2009 Sep 25.

PMID:
19782690
6.

New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations.

Moulin A, Demange L, Ryan J, Mousseaux D, Sanchez P, Bergé G, Gagne D, Perrissoud D, Locatelli V, Torsello A, Galleyrand JC, Fehrentz JA, Martinez J.

J Med Chem. 2008 Feb 14;51(3):689-93. doi: 10.1021/jm701292s. Epub 2008 Jan 15.

PMID:
18193826
7.

Trisubstituted 1,2,4-triazoles as ligands for the ghrelin receptor: on the significance of the orientation and substitution at position 3.

Moulin A, Demange L, Ryan J, M'Kadmi C, Galleyrand JC, Martinez J, Fehrentz JA.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):164-8. Epub 2007 Nov 4.

PMID:
18023181
8.

Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluations.

Moulin A, Demange L, Bergé G, Gagne D, Ryan J, Mousseaux D, Heitz A, Perrissoud D, Locatelli V, Torsello A, Galleyrand JC, Fehrentz JA, Martinez J.

J Med Chem. 2007 Nov 15;50(23):5790-806. Epub 2007 Oct 10.

PMID:
17927165
9.

Effect of dronedarone on renal function in healthy subjects.

Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, Biollaz J.

Br J Clin Pharmacol. 2007 Dec;64(6):785-91. Epub 2007 Jul 27.

10.

Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor. 1.

Demange L, Boeglin D, Moulin A, Mousseaux D, Ryan J, Bergé G, Gagne D, Heitz A, Perrissoud D, Locatelli V, Torsello A, Galleyrand JC, Fehrentz JA, Martinez J.

J Med Chem. 2007 Apr 19;50(8):1939-57. Epub 2007 Mar 22.

PMID:
17375904
11.

Regulation of ERK1/2 activity by ghrelin-activated growth hormone secretagogue receptor 1A involves a PLC/PKCvarepsilon pathway.

Mousseaux D, Le Gallic L, Ryan J, Oiry C, Gagne D, Fehrentz JA, Galleyrand JC, Martinez J.

Br J Pharmacol. 2006 Jun;148(3):350-65.

12.

Cholecystokinin 1 receptor modulates the MEKK1-induced c-Jun trans-activation: structural requirements of the receptor.

Ibarz G, Oiry C, Carnazzi E, Crespy P, Escrieut C, Fourmy D, Galleyrand JC, Gagne D, Martinez J.

Br J Pharmacol. 2006 Apr;147(8):951-8.

13.

Cross-interactions of two p38 mitogen-activated protein (MAP) kinase inhibitors and two cholecystokinin (CCK) receptor antagonists with the CCK1 receptor and p38 MAP kinase.

Morel C, Ibarz G, Oiry C, Carnazzi E, Bergé G, Gagne D, Galleyrand JC, Martinez J.

J Biol Chem. 2005 Jun 3;280(22):21384-93. Epub 2005 Mar 16.

14.

New active series of growth hormone secretagogues.

Guerlavais V, Boeglin D, Mousseaux D, Oiry C, Heitz A, Deghenghi R, Locatelli V, Torsello A, Ghé C, Catapano F, Muccioli G, Galleyrand JC, Fehrentz JA, Martinez J.

J Med Chem. 2003 Mar 27;46(7):1191-203.

PMID:
12646029
15.

C-terminal heptapeptide of gastrin inhibits astrocytomas motility by interacting with a new gastrin binding site.

Pannequin J, Oiry C, Morel C, Kucharczak J, Camby I, Kiss R, Gagne D, Galleyrand JC, Martinez J.

J Pharmacol Exp Ther. 2002 Jul;302(1):274-82.

PMID:
12065727
16.

The third intracellular loop of the rat and mouse cholecystokinin-A receptors is responsible for different patterns of gene activation.

Poosti R, di Malta L, Gagne D, Bernad N, Galleyrand JC, Escrieut C, Silvente-Poirot S, Fourmy D, Martinez J.

Mol Pharmacol. 2000 Dec;58(6):1381-8.

PMID:
11093777
17.

A synthetic glycine-extended bombesin analogue interacts with the GRP/bombesin receptor.

Oiry C, Pannequin J, Bernad N, Artis AM, Galleyrand JC, Devin C, Cristau M, Fehrentz JA, Martinez J.

Eur J Pharmacol. 2000 Sep 1;403(1-2):17-25.

PMID:
10969139
18.

L-365,260 inhibits in vitro acid secretion by interacting with a PKA pathway.

Oiry C, Pannequin J, Cormier A, Galleyrand JC, Martinez J.

Br J Pharmacol. 1999 May;127(1):259-67.

19.

CholecystokininB receptor from human Jurkat lymphoblastic T cells is involved in activator protein-1-responsive gene activation.

Oiry C, Gagne D, Cottin E, Bernad N, Galleyrand JC, Bergé G, Lignon MF, Eldin P, Le Cunff M, Léger J, Clerc P, Fourmy D, Martinez J.

Mol Pharmacol. 1997 Aug;52(2):292-9.

PMID:
9271352
20.

Synthesis and biological activities of some human gastrin analogs.

Lima-Leite AC, Fulcrand P, Galleyrand JC, Berge G, Aumelas A, Bali JP, Castel J, Martinez J.

Braz J Med Biol Res. 1996 Oct;29(10):1253-63.

PMID:
9181094
21.

The influence of gastrin and/or cholecystokinin antagonists on the proliferation of three human astrocytic tumor cell lines.

Camby I, Salmon I, Oiry C, Galleyrand JC, Nagy N, Danguy A, Brotchi J, Pasteels JL, Martinez J, Kiss R.

Neuropeptides. 1996 Oct;30(5):433-7.

PMID:
8923504
22.

Are C-terminal octapeptide of cholecystokinin and [Leu11]gastrin-(5-17) different in stimulating acid secretion in isolated rabbit gastric glands?

Oiry C, Galleyrand JC, Lima-Leite AC, Fulcrand P, Martinez J.

Eur J Pharmacol. 1995 Dec 29;294(2-3):511-9.

PMID:
8750713
23.

Cholecystokinin and gastrin are not equally sensitive to GTP gamma S at CCKB receptors: importance of the sulphated tyrosine.

Lallement JC, Oiry C, Lima-Leite AC, Lignon MF, Fulcrand P, Galleyrand JC, Martinez J.

Eur J Pharmacol. 1995 Jul 18;290(2):61-7.

PMID:
8575534
24.

Synthesis and characterization of a new labeled gastrin ligand, 125-I-BH-[Leu15]-gastrin-(5-17), on binding to canine fundic mucosal cells and Jurkat cells.

Galleyrand JC, Lima-Leite AC, Lallement JC, Lignon MF, Bernad N, Fulcrand P, Martinez J.

Int J Pept Protein Res. 1994 Oct;44(4):348-56.

PMID:
7875937
25.

Gastrin13 and the C-terminal octapeptide of cholecystokinin are differently coupled to G-proteins in guinea-pig brain membranes.

Lallement JC, Galleyrand JC, Lima-Leite AC, Fulcrand P, Martinez J.

Eur J Pharmacol. 1994 May 17;267(3):297-305.

PMID:
8088368
26.

Gastrin13 binds to CCKB brain membrane receptors coupled to G protein in guinea pig brain membranes.

Lallement JC, Galleyrand JC, Lima-Leite AC, Fulcrand P, Martinez J.

Ann N Y Acad Sci. 1994 Mar 23;713:346-9. No abstract available.

PMID:
8185183
27.

Biological effects of human gastrin I and II chemically modified at the C-terminal tetrapeptide amide.

Galleyrand JC, Fulcrand P, Bali JP, Rodriguez M, Magous R, Laur J, Martinez J.

Peptides. 1992 May-Jun;13(3):519-25.

PMID:
1523164
28.

Characterization of a gastrin-type receptor on rabbit gastric parietal cells using L365,260 and L364,718.

Roche S, Bali JP, Galleyrand JC, Magous R.

Am J Physiol. 1991 Feb;260(2 Pt 1):G182-8.

PMID:
1996638
29.

Conformational and biological properties of the Ala10 analogue of human des-Trp1,Nle12-minigastrin.

Mammi S, Foffani MT, Peggion E, Galleyrand JC, Bali JP, Simonetti M, Göhring W, Moroder L, Wünsch E.

Biochemistry. 1989 Sep 5;28(18):7182-8.

PMID:
2819061
30.

Common or distinct receptors for gastrin and cholecystokinin in gastric mucosa?

Magous R, Galleyrand JC, Bali JP.

Biochim Biophys Acta. 1989 Mar 6;1010(3):357-62.

PMID:
2920184
31.

[Is forskolin a stimulant of gastric secretion?].

Choquet A, Magous R, Galleyrand JC, Bali JP.

C R Seances Soc Biol Fil. 1988;182(3):335-43. French.

PMID:
2852529
32.

Uncorrected pre-ejection period: a simple non-invasive measurement for pharmacodynamic screening of inotropic activity.

Rousson D, Galleyrand J, Silie M, Boissel JP.

Eur J Clin Pharmacol. 1987;31(5):559-62.

PMID:
3830241
33.

Systolic time intervals in evaluation of the negative inotropic effect after single oral doses of mexiletine and disopyramide.

Rousson D, Piolat C, Galleyrand J, Ferry S, Boissel JP.

Eur J Clin Pharmacol. 1986;30(3):263-8.

PMID:
3732360
34.

Effects of human pancreatic tumor growth hormone-releasing hormone (hpGRH1-44-NH2) on immunoreactive and bioactive plasma growth hormone in normal young men.

Sassolas G, Chatelain P, Cohen R, Boissel JP, Laporte S, Galleyrand J, Claustrat B, Elmcharfi A, Chayvialle JA, Cohen H, et al.

J Clin Endocrinol Metab. 1984 Oct;59(4):705-9.

PMID:
6148353
35.

[Somatocrinin (GRF) stimulates the liberation of biologically active somatotropin (GH) in adult man].

Sassolas G, Boissel JP, Cohen R, Chatelain P, Laporte S, Galleyrand J, Cohen H, Ferry S, Maire P.

C R Seances Acad Sci III. 1983;296(23):1113-6. French.

PMID:
6416624

Supplemental Content

Loading ...
Support Center